# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

# B Applicant

Microbiologics, Inc.

# C Proprietary and Established Names

Cepheid Xpert SA Nasal Complete Control Panel

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>PMN</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3920 -Assayed Quality ControlMaterial For ClinicalMicrobiology Assays</td><td rowspan=1 colspan=1>IM - Immunology &amp;MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

To obtain a Substantial Equivalence determination for the Cepheid Xpert SA Nasal Complete Control Panel for use with the Cepheid Xpert SA Nasal Complete Assay on the GeneXpert Dx System.

# B Measurand:

Nucleic acid quality control material from inactivated Methicillin-Resistant Staphylococcus aureus (MRSA, positive control 1), Staphylococcus aureus (SA, positive control 2) and Staphylococcus epidermidis (negative control).

# C Type of Test:

The Cepheid Xpert SA Nasal Complete Control Panel is an external assayed positive and negative quality control material to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Staphylococcus aureus (MRSA) and

Staphylococcus aureus (SA) performed with the Cepheid Xpert SA Nasal Complete Assay on the GeneXpert Dx System.

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Cepheid Xpert SA Nasal Complete Control Panel is intended for use as an external assayed positive and negative quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Methicillin-Resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) performed with the Cepheid Xpert SA Nasal Complete Assay on the GeneXpert Dx System. The controls comprise cultured and inactivated Methicillin-Resistant Staphylococcus aureus as the positive control 1; Staphylococcus aureus as the positive control 2; Staphylococcus epidermidis as the negative control.

The Cepheid Xpert SA Nasal Complete Control Panel is not intended to replace manufacturer controls provided with the Cepheid Xpert SA Nasal Complete Assay.

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

For in vitro diagnostic use only.

This product is not intended to replace the manufacturer controls provided with the Cepheid Xpert SA Nasal Complete Assay.

# D Special Instrument Requirements:

The Cepheid Xpert SA Nasal Complete Control Panel is intended for use on the GeneXpert Dx System.

# IV Device/System Characteristics:

# A Device Description:

The Cepheid Xpert SA Nasal Complete Control Panel is used to monitor the DNA extraction, amplification and detection processes of the Cepheid Xpert SA Nasal Complete Assay. The Cepheid Xpert SA Nasal Complete Control Panel contains cultured microorganisms inactivated by heat treatments. Each Cepheid Xpert SA Nasal Complete Control Panel consists of 6 individually packaged Methicillin-Resistant Staphylococcus aureus (MRSA) positive control swabs (positive control 1); 6 individually wrapped methicillin-susceptible Staphylococcus aureus (MSSA) positive controls swabs (positive control 2); and 6 individually wrapped methicillinsusceptible Staphylococcus epidermidis (MSSE) negative control swabs. Each positive control 1 swab contains MRSA at a target level that is designed to provide reproducible performance above the limit of detection to produce positive results for each of the genes targeted by the Cepheid Xpert SA Nasal Complete Assay: Staphylococcal protein A gene spa (SPA), methicillin resistance gene mecA (mec), and the Staphylococcal cassette chromosome (SCC). Each positive control 2 swab contains MSSA at a target level designed to provide reproducible performance

above the limit of detection of the spa gene target of the Cepheid Xpert SA Nasal Complete Assay. The negative control swab contains MSSE which is not targeted/detected by the Cepheid Xpert SA Nasal Complete Assay. Each swab is individually wrapped with a desiccant in a heatsealed foil pouch.

# B Principle of Operation:

The Cepheid Xpert SA Nasal Complete Control Panel is intended for use as external assayed quality control material for use in monitoring the DNA extraction, amplification and detection processes associated with the Cepheid Xpert SA Nasal Complete Assay on the GeneXpert Dx System.

V Substantial Equivalence Information:

A Predicate Device Name(s): Cepheid Xpert GBS LB Control Panel B Predicate 510(k) Number(s): K182472 C Comparison with Predicate(s):

Table 1. Comparison with the Predicate   

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K191168</td><td colspan="1" rowspan="1">K182472</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Cepheid Xpert SA Nasal CompleteControl Panel</td><td colspan="1" rowspan="1">Cepheid Xpert GBS LBControl Panel</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications for Use</td><td colspan="1" rowspan="1">External assayed positive andnegative quality control to monitorthe performance of in vitrolaboratory nucleic acid testingprocedures for the qualitativedetection of Methicillin-ResistantStaphylococcus aureus (MRSA) andStaphylococcus aureus (SA)performed with the Cepheid XpertSA Nasal Complete Assay on theGeneXpert Dx System. The controlscomprise cultured and inactivatedMethicillin-ResistantStaphylococcus aureus as thepositive control 1; Staphylococcusaureus as the positive control 2;Staphylococcus epidermidis as thenegative control.The Cepheid Xpert SA Nasal</td><td colspan="1" rowspan="1">External assayed positive andnegative quality controlmaterials to monitor theperformance of in vitrolaboratory nucleic acid testingprocedures for the qualitativedetection of Group BStreptococcus (GBS)performed with the CepheidXpert GBS LB Assay on theGeneXpert InstrumentSystem. The controlscomprise cultured andinactivated Streptococcusagalactiae as the positivecontrol and Lactobacillusacidophilus as the negativecontrol.The Cepheid Xpert GBS LB</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Complete Control Panel is notintended to replace manufacturercontrols provided with the CepheidXpert SA Nasal Complete Assay.</td><td colspan="1" rowspan="1">Control Panel is not intendedto replace the manufacturercontrols provided with thedevice.</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Inactivated microorganisms</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test System</td><td colspan="1" rowspan="1">Cepheid GeneXpert System</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Directions for Use</td><td colspan="1" rowspan="1">Process like a patient sample</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Steps Monitored</td><td colspan="1" rowspan="1">Extraction, amplification, anddetection</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Physical Format</td><td colspan="1" rowspan="1">Lyophilized swab</td><td colspan="1" rowspan="1">Lyophilized swab</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Positive Control 1:(MRSA) Methicillin-resistantStaphylococcus aureusPositive Control 2:(SA) Staphylococcus aureusNegative Control:Staphylococcus epidermidis</td><td colspan="1" rowspan="1">•  Positive Control:Streptococcus agalactiae•  Negative Control:Lactobacillus acidophilus</td></tr><tr><td colspan="1" rowspan="1">Assay Compatibility</td><td colspan="1" rowspan="1">Cepheid Xpert SA Nasal CompleteAssay (K100822)</td><td colspan="1" rowspan="1">Cepheid Xpert GBS LBAssay (K121539)</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI. Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline. CLSI Document EP25-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.

CLSI. Evaluation of Precision of Quantitative Measurement Procedures: Approved Guideline – Third Edition. CLSI Document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

ANSI. Sampling Procedures and Tables for Inspection by Attributes. ANSI/ASQ Z1.4-2003;   
2013.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

A study was performed to determine the reproducibility of the Cepheid Xpert SA Nasal Complete Control Panel using the Cepheid Xpert SA Nasal Complete Assay on the GeneXpert Dx System. Testing was done at three different locations over five days. At each location, two operators each tested three different lots of control material for a total of at least 90 test results each for the positive control 1, positive control 2 and the negative control swabs (3 sites x 5 days $_ { \textrm { X 2 } }$ operators $\mathbf { X } \geq 3$ replicates $= { \ge } 9 0$ replicates in total). Summaries of the results for both the positive and negative controls are provided in Table 2 and Table 3. On initial testing, one positive control 1 and two positive control 2 swabs produced “NO RESULT” because insufficient data were collected to determine the sample status. After retesting using new control swabs, all positive control swabs produced the expected positive results. Fourteen “INVALID” results due to failure of the Sample Processing Control, one “ERROR” due to system failure and one report of “NO RESULT” were observed with the negative control. After re-testing of new control swabs, all negative control swabs produced the expected negative results.

Table 2. Summary of results from the Reproducibility Study (qualitative)   

<table><tr><td rowspan=1 colspan=8>Positive Control 1 (Methicillin-Resistant Staphylococcus aureus)</td></tr><tr><td rowspan=1 colspan=1>Testlocation</td><td rowspan=1 colspan=1>Total TestsPerformed</td><td rowspan=1 colspan=1>INVALID</td><td rowspan=1 colspan=1>NORESULT1</td><td rowspan=1 colspan=1>ERROR</td><td rowspan=1 colspan=1>CorrectResult</td><td rowspan=1 colspan=1>IncorrectResult</td><td rowspan=1 colspan=1>PercentCorrect2</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>All sites</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=8>Positive Control 2 (Methicillin-Susceptible Staphylococcus aureus)</td></tr><tr><td rowspan=1 colspan=1>Testlocation</td><td rowspan=1 colspan=1>Total TestsPerformed</td><td rowspan=1 colspan=1>INVALID</td><td rowspan=1 colspan=1>NORESULT1</td><td rowspan=1 colspan=1>ERROR</td><td rowspan=1 colspan=1>CorrectResult</td><td rowspan=1 colspan=1>IncorrectResult</td><td rowspan=1 colspan=1>PercentCorrect2</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>All sites</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=8>Negative Control (Methicillin-Susceptible Staphylococcus epidermidis)</td></tr><tr><td rowspan=1 colspan=1>Testlocation</td><td rowspan=1 colspan=1>Total TestsPerformed</td><td rowspan=1 colspan=1>INVALID3</td><td rowspan=1 colspan=1>NORESULT1</td><td rowspan=1 colspan=1>ERROR4</td><td rowspan=1 colspan=1>CorrectResult</td><td rowspan=1 colspan=1>IncorrectResult</td><td rowspan=1 colspan=1>PercentCorrect²</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>All sites</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

1Number of NO RESULT responses observed; in each case new controls were tested, as indicated in the test protocol, and the expecte results were obtained. 2Data from test runs that produced any type of error response were not included in the Percent Correct analysis. 3Number of INVALID responses observed; in each case new controls were tested, as indicated in the test protocol, and the expected results were obtained. 4Number of ERROR responses observed; a new control was tested, as indicated in the test protocol, and the expected results were obtained.

Table 3. Summary of results from the Reproducibility Study (quantitative)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>MeanCt (%CV)</td></tr><tr><td rowspan=1 colspan=1>Testlocation</td><td rowspan=1 colspan=3>Positive Control 1</td><td rowspan=1 colspan=1>PositiveControl 2</td><td rowspan=1 colspan=1>NegativeControl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SPA</td><td rowspan=1 colspan=1>mec</td><td rowspan=1 colspan=1>SCC</td><td rowspan=1 colspan=1>SPA</td><td rowspan=1 colspan=1>SPC</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>27.0(2.7)</td><td rowspan=1 colspan=1>27.3(2.6)</td><td rowspan=1 colspan=1>28.5(2.3)</td><td rowspan=1 colspan=1>26.8(2.7)</td><td rowspan=1 colspan=1>32.0(4.2)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>28.1(2.3)</td><td rowspan=1 colspan=1>28.4(2.0)</td><td rowspan=1 colspan=1>29.6(1.9)</td><td rowspan=1 colspan=1>27.8(2.5)</td><td rowspan=1 colspan=1>31.8(3.5)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>27.8(2.2)</td><td rowspan=1 colspan=1>28.1(2.1)</td><td rowspan=1 colspan=1>29.3(2.1)</td><td rowspan=1 colspan=1>27.4(2.8)</td><td rowspan=1 colspan=1>32.1(4.4)</td></tr><tr><td rowspan=1 colspan=1>All sites</td><td rowspan=1 colspan=1>27.6(3.0)</td><td rowspan=1 colspan=1>27.9(2.8)</td><td rowspan=1 colspan=1>29.1(2.7)</td><td rowspan=1 colspan=1>27.3(3.0)</td><td rowspan=1 colspan=1>32.0(4.0)</td></tr></table>

SPC: Sample processing control Ct: Cycle Threshold; $\% \mathrm { C V }$ : Percent Coefficient of Variation

The reproducibility of the Cepheid Xpert SA Nasal Complete Control Panel within and between test locations, GeneXpert Instruments, operators, and lots was determined to be acceptable.

2. Linearity: Not applicable.

3. Analytical Specificity/Interference: Not applicable.

4. Assay Reportable Range: Not applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

# Traceability:

Not applicable.

# Stability:

1. Shelf-life was established through an Accelerated Stability Study that was performed with three lots of each Positive and Negative Control from the Cepheid Xpert SA Nasal Complete Control Panel. The two types of positive controls and the negative control were placed at elevated temperatures of $4 3 ^ { \circ } \mathrm { C }$ , $5 3 ^ { \circ } \mathrm { C }$ and $6 3 ^ { \circ } \mathrm { C }$ . The positive controls were tested in replicates of four at each of the four time points (Day 0, Day 14, Day 28 and Day 42). The negative controls were tested in duplicate at two time points (Day 0 and Day 42). The data provided no evidence of product degradation under the conditions tested. A shelf-life claim of 9 months at $2 { - } 2 5 ^ { \circ } \mathrm { C }$ is acceptable. This shelf-life claim could be modified based on the results of the Real-Time Stability Study.

2. A Real-Time Stability, Shelf-Life Study is in process. Under a 10-point regression design, three lots of each control will be incubated at two temperatures $2 { - } 8 ^ { \circ } \mathrm { C }$ and $2 5 ^ { \circ } \mathrm { C }$ ). Regression analysis will be performed at the end of the study to evaluate performance and determine if the acceptance criteria are met. At that time, the expiration date will be updated to the time point at which all criteria are met.

3. An In-Use Stability Study was done to determine how long the positive and negative controls would remain stable after reconstitution. Controls from a single lot were rehydrated and kept at room temperature for different time periods prior to testing. All results were as expected and indicate that Cepheid Xpert SA Nasal Complete Control Panel swabs may be used up to five hours following rehydration.

6. Detection Limit: Not applicable.

7. Assay Cut-Off: Not applicable.

# B Comparison Studies:

1. Method Comparison with Predicate Device: Not applicable.

2. Matrix Comparison: Not applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

# D Clinical Cut-Off:

Not applicable.

# E Expected Values/Reference Range:

The Cepheid Xpert SA Nasal Complete Control Panel is a qualitative control expected to produce the results described in Table 4 when tested with the Cepheid Xpert SA Nasal Complete assay using the GeneXpert Dx System.

Table 4: Expected values   

<table><tr><td colspan="1" rowspan="1">Control</td><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Expected Assay Result</td><td colspan="1" rowspan="1">Interpretation</td></tr><tr><td colspan="1" rowspan="1">Positive Control 1</td><td colspan="1" rowspan="1">Methicillin-ResistantS. aureus (MRSA)</td><td colspan="1" rowspan="1">MRSA POSITIVE;SA POSITIVE</td><td colspan="1" rowspan="1">MRSA target DNAdetected; SA targetDNA detected. AllMRSA targets (spa,mecA and SCCmec)have a Ct within thevalid range andendpoint above thethreshold setting.</td></tr><tr><td colspan="1" rowspan="1">Positive Control 2</td><td colspan="1" rowspan="1">Methicillin-Susceptible S.aureus</td><td colspan="1" rowspan="1">MRSA NEGATIVE;SA POSITIVE</td><td colspan="1" rowspan="1">MRSA target DNA notdetected; SA targetDNA detected. SAtarget (spa) has a Ctwithin the valid rangeand endpoint above thethreshold setting.Target DNA forSCCmec and/or mecAis not detected.</td></tr><tr><td colspan="1" rowspan="1">Negative Control</td><td colspan="1" rowspan="1">Methicillin-Susceptible S.epidermidis</td><td colspan="1" rowspan="1">MRSA NEGATIVE;SA NEGATIVE</td><td colspan="1" rowspan="1">SA target DNA notdetected. SA target(spa) DNA is notdetected. Target DNAfor mecA and/orSCCmec may or maynot be detected.</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.